Tamoxifen, a partial agonist of ER, has been the most commonly used hormone therapy for decades for premenopausal women with breast cancer [18], whereas after menopause, women switch to an aromatase inhibitor that blocks the conversion of testosterone into estrogens. Here, ESR1 is linked to breast carcinoma.